How synthetic data accelerates oncology research and drug development 

[MDSHAFIQUL/Adobe Stock]

Synthetic data in oncology is transforming how researchers and developers approach real-world evidence. They often need this evidence to test hypotheses, predict outcomes and develop algorithms. But privacy constraints and access related to patient data can create delays and lengthen project timelines.

Oncology drug researchers and developers have recently begun using synthetic data in oncology to get around the privacy constraints and access issues related to patient data that create delays and lengthen project timelines.

Conceptually, synthetic data in oncology is about taking private patient information and enabling researchers to access the data without compromising privacy, offering a significant tool for current oncology research processes.

Traditional vs. new data approaches in oncology research

Traditionally, oncology researchers and drug developers have relied on t…

Read more
  • 0

The new National Cancer Plan launches with goal of cutting cancer death rate by half in 25 years

[Image courtesy of National Institutes of Health]

Today, the U.S. Department of Health and Human Services (HHS) debuted the National Cancer Plan with an ambitious albeit vague quest to “end cancer as we know it.”

Specifically, the initiative will serves as a guideline to support President Biden’s Cancer Moonshot objectives, which aims to reduce the cancer mortality rate by 50% over a 25-year period.

NCI will lead the National Cancer Plan and Cancer Moonshot program

HHS will put the National Institutes of Health’s (NIH) National Cancer Institute (NCI) in charge of the program, which supports the Cancer Moonshot initiative from President and First Lady Biden.

The President’s Cancer Moonshot has galvanized the goal of advancing the fight against cancer,” said Dr. Monica M. Bertagnolli, National Cancer Institute director, in a press release.

Despite Biden’s focus on ramping up oncology res…

Read more
  • 0